An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1844-1855

  Cox, Georgina ^a   Koteva, Kalinka ^a   Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibiotic adjuvants; Intrinsic antibiotic resistance; Pathogens; Resistome

Indexed keywords

ADJUVANT; ANTHRACYCLINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRACYCLINONE DERIVATIVE; ANTIBIOTIC AGENT; AVIDINORUBICIN; DAUNORUBICIN; DECILORENE; DECILORUBICIN; DOXORUBICIN; ERYTHROMYCIN; GRAM POSITIVE ANTIBIOTIC AGENT; LINEZOLID; NOGALAMYCIN; NOVOBIOCIN; POLYMYXIN B; RIFAMPICIN; SUGAR; UNCLASSIFIED DRUG; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DNA DIRECTED RNA POLYMERASE; OXAZOLIDINONE DERIVATIVE; RNA POLYMERASE BETA SUBUNIT;

ACINETOBACTER BAUMANNII; ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; ESCHERICHIA COLI; FERMENTATION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM;

ACETAMIDES; ACINETOBACTER BAUMANNII; ANTHRACYCLINES; ANTI-BACTERIAL AGENTS; DNA-DIRECTED RNA POLYMERASES; DRUG SYNERGISM; ESCHERICHIA COLI; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OXAZOLIDINONES; RIFAMPIN; STREPTOMYCES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902472863     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku057     Document Type: Article

References (68)

1. CDC. Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: CDC, 2013.
2. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1: i29-36.
3. Hope R, Livermore DM, Brick G et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii65-74.
4. Eaton L. C. difficile cases rising, but MRSA rates falling. BMJ 2007; 335: 177.
5. Feng PJ, Kallen AJ, Ellingson K et al. Clinical incidence of methicillinresistant Staphylococcus aureus (MRSA) colonization or infection as a proxy measure for MRSA transmission in acute care hospitals. Infect Control Hosp Epidemiol 2011; 32: 20-5.
6. Kallen AJ, Mu Y, Bulens S et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304: 641-8.
7. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
8. Lee JH, Jeong SH, Cha SS et al. New disturbing trend in antimicrobial resistance of Gram-negative pathogens. PLoS Pathog 2009; 5: e1000221.
9. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 2010; 362: 1804-13.
10. Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol 2013; 303: 287-292.
11. Yahav D, Lador A, Paul M et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
12. Livermore DM. Doripenem: antimicrobial profile and clinical potential. Diagn Microbiol Infect Dis 2009; 63: 455-8.
13. Randall CP, Mariner KR, Chopra I et al. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother 2013; 57: 637-9.
14. Liu A, Tran L, Becket E et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother 2010; 54: 1393-403.
15. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992; 56: 395-411.
16. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
17. Molina J, Cordero E, Pachon J. New information about the polymyxin/ colistin class of antibiotics. Expert Opin Pharmacother 2009; 10: 2811-28.
18. Blair JMA, Piddock LJV. Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update. Curr Opin Microbiol 2009; 12: 512-9.
19. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001; 3: 225-36.
20. Gomez MJ, Neyfakh AA. Genes involved in intrinsic antibiotic resistance of Acinetobacter baylyi. Antimicrob Agents Chemother 2006; 50: 3562-7.
21. Fajardo A, Martinez-Martin N, Mercadillo M et al. The neglected intrinsic resistome of bacterial pathogens. PLoS One 2008; 3: e1619.
22. Ejim L, Farha MA, Falconer SB et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 2011; 7: 348-50.
23. Taylor PL, Rossi L, De Pascale G et al. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem Biol 2012; 7: 1547-55.
24. Thaker MN,WangW, Spanogiannopoulos P et al. Identifying producers of antibacterial compounds by screening for antibiotic resistance. Nat Biotechnol 2013; 31: 922-927.
25. CLSI. Methods for Dilution Antimicrobial Susceptibility Testing of Bacteria that Grow Aerobically. Wayne, PA, 2012.
26. Zhang SS, Liu HX, Yuan ZB et al. A reproducible, simple, and sensitive high-performance capillary electrophoresis method for simultaneous determination of capreomycin, ofloxacin and pasiniazide in urine. J Pharm Biomed Anal 1998; 17: 617-22.
27. Kieser T, Bibb MJ, Buttner MJ et al. Practical Streptomyces Genetics. Norwich, UK: John Innes Foundation Press, 2000.
28. Heuer H, Krsek M, Baker P et al. Analysis of actinomycete communities by specific amplification of genes encoding 16S rRNA and gel-electrophoretic separation in denaturing gradients. Appl Environ Microbiol 1997; 63: 3233-41.
29. Sims PJ, Waggoner AS, Wang CH et al. Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles. Biochemistry 1974; 13: 3315-30.
30. Bohnert JA, Karamian B, Nikaido H. Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. Antimicrob Agents Chemother 2010; 54: 3770-5.
31. Baba T, Ara T, Hasegawa M et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2006; 2: 2006 0008.
32. Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 2000; 156: 1471-81.
33. Williams KJ, Piddock LJ. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 597-603.
34. Ma D, Cook DN, Alberti M et al. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli. J Bacteriol 1993; 175: 6299-313.
35. Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibioticresistance (Mar) mutants. J Bacteriol 1996; 178: 306-8.
36. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
37. Westman EL, Canova MJ, Radhi IJ et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol 2012; 19: 1255-64.
38. Ishigami K, Hayakawa Y, Seto H. Cororubicin, a new anthracycline antibiotic generating active oxygen in tumor-cells. J Antibiot (Tokyo) 1994; 47: 1219-25.
39. Ishii K, Nishimura Y, Naganawa H et al. The structure of decilorubicin. J Antibiot (Tokyo) 1984; 37: 344-53.
40. Noecker L, Duarte F, Giuliano RM. Synthetic studies of the cororubicin oligosaccharide: glycosylation of branched amino and nitro sugars. J Carbohydr Chem 1998; 17: 39-48.
41. Aoki M, Shirai H, Nakayama N et al. Structural studies on avidinorubicin, a novel anthracycline with platelet-aggregation inhibitory activity. J Antibiot (Tokyo) 1991; 44: 635-45.
42. Nishimura Y, Ishii K. The absolute-configuration of decilonitrose, a sugar component of decilorubicin, is undoubtedly 2,3,6-trideoxy-3-Cmethyl-3-nitro-L-ribo-hexopyranose. J Antibiot 1990; 43: 54-61.
43. Wiley PF, Elrod DW, Houser DJ et al. Nogalamycin-stereochemistry and chemical modification. J Org Chem 1979; 44: 4030-8.
44. Wiley PF. Improved anti-tumor activity by modification of nogalamycin. J Nat Prod 1979; 42: 569-82.
45. Ishii K, Kondo S, Nishimura Y et al. Decilorubicin, a new anthracycline antibiotic. J Antibiot (Tokyo) 1983; 36: 451-3.
46. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial Combinations. Baltimore, MD: Williams and Wilkins, 2005.
47. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
48. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2013. http://www.eucast.org/fileadmin/src/media/PDFs/ EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf (1 March 2014, date last accessed).
49. Dixon RA, Chopra I. Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli. J Antimicrob Chemother 1986; 18: 557-63.
50. Balemans W, Vranckx L, Lounis N et al. Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria. Antimicrob Agents Chemother 2012; 56: 4131-9.
51. Schumacher A, Trittler R, Bohnert JA et al. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother 2007; 59: 1261-4.
52. Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine b-naphthylamide (PAbN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One 2013; 8: e60666.
53. Morones-Ramirez JR, Winkler JA, Spina CS et al. Silver enhances antibiotic activity against Gram-negative bacteria. Sci Transl Med 2013; 5: 190ra81.
54. Calvori C, Frontali L, Leoni L et al. Effect of rifamycin on protein synthesis. Nature 1965; 207: 417-8.
55. Campbell EA, Korzheva N, Mustaev A et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901-12.
56. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988; 202: 45-58.
57. Rodriguez-Verdugo A, Gaut BS, Tenaillon O. Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. BMC Evol Biol 2013; 13: 50.
58. Xu M, Zhou YN, Goldstein BP et al. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J Bacteriol 2005; 187: 2783-92.
59. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 2011; 55: 947-53.
60. Coyne S, Guigon G, Courvalin P et al. Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. Antimicrob Agents Chemother 2010; 54: 333-40.
61. Rosenfeld N, Bouchier C, Courvalin P et al. Expression of the resistance-nodulation-cell division pump AdeIJK in Acinetobacter baumannii is regulated by AdeN, a TetR-type regulator. Antimicrob Agents Chemother 2012; 56: 2504-10.
62. Coyne S, Rosenfeld N, Lambert T et al. Overexpression of resistancenodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 4389-93.
63. Farha MA, Leung A, Sewell EWet al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to b-lactams. ACS Chem Biol 2013; 8: 226-33.
64. Li LH, Kuentzel SL, Murch LL et al. Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 leukemia. Cancer Res 1979; 39: 4816-22.
65. Williams LD, Egli M, Qi G et al. Structure of nogalamycin bound to a DNA hexamer. Proc Natl Acad Sci USA 1990; 87: 2225-9.
66. Damier-Piolle L, Magnet S, Bremont S et al. AdeIJK, a resistancenodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 557-62.
67. Nakashima R, Sakurai K, Yamasaki S et al. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 2011; 480: 565-9.
68. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.